Keryx Biopharmaceuticals Company Profile (NASDAQ:KERX)

About Keryx Biopharmaceuticals (NASDAQ:KERX)

Keryx Biopharmaceuticals logoKeryx Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. Auryxia is marketed in Japan under the brand name Riona. It is investigating the use of ferric citrate for the treatment of iron deficiency anemia (IDA) in adults with non-dialysis dependent (NDD), CKD and NDD-CKD. It focuses on Keryx Patient Plus program to assist with patient accessibility to Auryxia. It has completed a Phase II clinical trial and a Phase III clinical trial of ferric citrate to gain Food and Drug Administration approval to use ferric citrate in patients with NDD-CKD.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:KERX
  • CUSIP: 49251510
  • Web:
  • Market Cap: $792.06 million
  • Outstanding Shares: 118,750,000
Average Prices:
  • 50 Day Moving Avg: $7.26
  • 200 Day Moving Avg: $6.76
  • 52 Week Range: $4.11 - $8.38
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -20.88
  • P/E Growth: -0.05
Sales & Book Value:
  • Annual Revenue: $42.83 million
  • Price / Sales: 18.52
  • Book Value: $0.22 per share
  • Price / Book: 30.36
  • EBITDA: ($121,750,000.00)
  • Net Margins: -431.89%
  • Return on Equity: -2,902.87%
  • Return on Assets: -78.46%
  • Debt-to-Equity Ratio: 4.88%
  • Current Ratio: 5.76%
  • Quick Ratio: 5.16%
  • Average Volume: 1.21 million shs.
  • Beta: 5.13
  • Short Ratio: 12.49

Frequently Asked Questions for Keryx Biopharmaceuticals (NASDAQ:KERX)

What is Keryx Biopharmaceuticals' stock symbol?

Keryx Biopharmaceuticals trades on the NASDAQ under the ticker symbol "KERX."

How were Keryx Biopharmaceuticals' earnings last quarter?

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) posted its earnings results on Thursday, July, 27th. The company reported ($0.77) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by $0.60. The company had revenue of $15.10 million for the quarter, compared to analysts' expectations of $14.51 million. Keryx Biopharmaceuticals had a negative return on equity of 2,902.87% and a negative net margin of 431.89%. The firm's quarterly revenue was up 62.4% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.42) EPS. View Keryx Biopharmaceuticals' Earnings History.

When will Keryx Biopharmaceuticals make its next earnings announcement?

Keryx Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Keryx Biopharmaceuticals.

Where is Keryx Biopharmaceuticals' stock going? Where will Keryx Biopharmaceuticals' stock price be in 2017?

5 brokerages have issued 1-year price targets for Keryx Biopharmaceuticals' shares. Their predictions range from $7.00 to $9.00. On average, they expect Keryx Biopharmaceuticals' share price to reach $7.50 in the next twelve months. View Analyst Ratings for Keryx Biopharmaceuticals.

What are analysts saying about Keryx Biopharmaceuticals stock?

Here are some recent quotes from research analysts about Keryx Biopharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Keryx is making efforts to expand the label of Auryxia. With Auryxia being the only approved product in Keryx’s portfolio, the company is entirely dependent on Auryxia for growth. Auryxia faces stiff competition in the U.S. from existing players, apart from over-the-counter drugs like some calcium carbonate and metal-based products. Apart from competition, Keryx may face strong pricing pressure for Auryxia. However, The  FDA accepted for review the supplemental New Drug Application (sNDA) for Auryxia tablets for the iron-deficiency anemia (IDA) indication and has set the Prescription Drug User Fee Act (PDUFA) target action date on Nov 6, 2017. A potential approval should increase sales. Shares of the company have outperformed the industry year to date. Estimates have remained stable ahead of the Q3 earnings results. The company has a negative record of earnings surprises in recent quarters." (10/16/2017)
  • 2. Maxim Group analysts commented, "Summary Conclusion: We see little to no effect from this news on the commercial outlook for Auryxia." (7/20/2017)

Who are some of Keryx Biopharmaceuticals' key competitors?

Who are Keryx Biopharmaceuticals' key executives?

Keryx Biopharmaceuticals' management team includes the folowing people:

  • Michael W. Rogers, Chairman of the Board
  • Gregory Paul Madison, Chief Executive Officer, Director
  • Scott A. Holmes, Chief Financial Officer, Treasurer
  • Christine A. Carberry, Chief Operating Officer
  • Douglas M. Jermasek, Vice President of Marketing and Strategy
  • Brian R. Adams, General Counsel, Secretary
  • Lora Pike, Senior Director
  • John F. Neylan, Chief Medical Officer
  • Kevin J. Cameron, Independent Director
  • Mark J. Enyedy, Independent Director

How do I buy Keryx Biopharmaceuticals stock?

Shares of Keryx Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Keryx Biopharmaceuticals' stock price today?

One share of Keryx Biopharmaceuticals stock can currently be purchased for approximately $6.68.

MarketBeat Community Rating for Keryx Biopharmaceuticals (NASDAQ KERX)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  370 (Vote Outperform)
Underperform Votes:  217 (Vote Underperform)
Total Votes:  587
MarketBeat's community ratings are surveys of what our community members think about Keryx Biopharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Keryx Biopharmaceuticals (NASDAQ:KERX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.20)
Consensus Price Target: $7.50 (12.28% upside)
Consensus Price Target History for Keryx Biopharmaceuticals (NASDAQ:KERX)
Price Target History for Keryx Biopharmaceuticals (NASDAQ:KERX)
Analysts' Ratings History for Keryx Biopharmaceuticals (NASDAQ:KERX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/27/2017Maxim GroupSet Price TargetBuy$9.00HighView Rating Details
7/25/2017Morgan StanleyReiterated RatingEqual Weight$4.00 -> $7.00LowView Rating Details
7/25/2017Cowen and CompanyReiterated RatingMarket PerformMediumView Rating Details
1/11/2017Citigroup Inc.UpgradeSell -> Neutral$7.00N/AView Rating Details
11/19/2016FBR & CoReiterated RatingHoldN/AView Rating Details
9/8/2016JMP SecuritiesReiterated RatingOutperformN/AView Rating Details
8/2/2016Raymond James Financial, Inc.Boost Price TargetOutperform$7.00 -> $10.00N/AView Rating Details
8/2/2016Ladenburg Thalmann Financial ServicesBoost Price TargetBuy$9.00 -> $10.00N/AView Rating Details
8/2/2016Brean CapitalDowngradeBuy -> HoldN/AView Rating Details
8/2/2016Stifel NicolausDowngradeBuy -> HoldN/AView Rating Details
3/29/2016BTIG ResearchReiterated RatingSell$2.50N/AView Rating Details
2/26/2016J P Morgan Chase & CoDowngradeOverweight -> NeutralN/AView Rating Details
(Data available from 10/18/2015 forward)


Earnings History for Keryx Biopharmaceuticals (NASDAQ:KERX)
Earnings by Quarter for Keryx Biopharmaceuticals (NASDAQ:KERX)
Earnings History by Quarter for Keryx Biopharmaceuticals (NASDAQ KERX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017($0.17)N/AView Earnings Details
7/27/2017Q2 2017($0.17)($0.77)$14.51 million$15.10 millionViewN/AView Earnings Details
5/4/2017Q1 2017($0.18)($0.21)$10.19 million$11.82 millionViewListenView Earnings Details
3/1/2017Q4 2016($0.25)($0.32)$9.65 million$9.53 millionViewListenView Earnings Details
11/9/2016Q316($0.22)($0.39)$5.53 million$6.30 millionViewListenView Earnings Details
8/1/2016Q216($0.28)($0.42)$8.60 million$9.30 millionViewListenView Earnings Details
4/28/2016Q116($0.26)($0.39)$6.63 million$6.80 millionViewListenView Earnings Details
2/25/2016Q415($0.25)($0.36)$5.68 million$5.80 millionViewListenView Earnings Details
10/29/2015Q3 2015($0.25)($0.29)$3.91 million$4.21 millionViewListenView Earnings Details
8/5/2015Q215($0.26)($0.26)$2.86 million$2.50 millionViewListenView Earnings Details
5/4/2015Q115($0.30)($0.28)$2.45 million$1.20 millionViewListenView Earnings Details
2/27/2015Q414($0.38)($0.44)$1.70 million$0.57 millionViewListenView Earnings Details
11/6/2014Q314($0.27)($0.38)$0.39 million$0.26 millionViewListenView Earnings Details
8/7/2014Q214($0.23)($0.24)$0.28 millionViewListenView Earnings Details
5/8/2014Q114($0.10)($0.15)$9.91 million$10.00 millionViewListenView Earnings Details
3/12/2014Q413($0.16)($0.21)$2.22 millionViewListenView Earnings Details
11/5/2013Q313($0.11)($0.19)$2.22 millionViewListenView Earnings Details
8/1/2013Q2 2013($0.10)($0.14)ViewListenView Earnings Details
5/7/2013Q1 2013($0.01)($0.03)$5.83 million$7.00 millionViewListenView Earnings Details
3/12/2013Q4 2012($0.08)($0.09)ViewListenView Earnings Details
11/7/2012Q312($0.07)($0.08)ViewN/AView Earnings Details
8/7/2012($0.09)($0.02)ViewN/AView Earnings Details
5/8/2012($0.12)($0.13)ViewN/AView Earnings Details
2/29/2012($0.14)($0.12)ViewN/AView Earnings Details
8/8/2011($0.03)($0.05)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Keryx Biopharmaceuticals (NASDAQ:KERX)
Current Year EPS Consensus Estimate: $-1.29 EPS
Next Year EPS Consensus Estimate: $-0.32 EPS


Dividend History for Keryx Biopharmaceuticals (NASDAQ:KERX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Keryx Biopharmaceuticals (NASDAQ:KERX)
Insider Ownership Percentage: 2.58%
Institutional Ownership Percentage: 65.19%
Insider Trades by Quarter for Keryx Biopharmaceuticals (NASDAQ:KERX)
Institutional Ownership by Quarter for Keryx Biopharmaceuticals (NASDAQ:KERX)
Insider Trades by Quarter for Keryx Biopharmaceuticals (NASDAQ:KERX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/5/2017Brian AdamsGeneral CounselSell630$7.19$4,529.70View SEC Filing  
10/5/2017Greg MadisonInsiderSell895$7.19$6,435.05View SEC Filing  
7/31/2017John F. NeylanInsiderSell1,445$7.14$10,317.30View SEC Filing  
7/28/2017Scott A. HolmesCFOSell1,236$6.96$8,602.56View SEC Filing  
7/24/2017John F. NeylanInsiderSell1,214$7.27$8,825.78View SEC Filing  
7/5/2017Brian AdamsGeneral CounselSell641$7.67$4,916.47View SEC Filing  
7/5/2017Greg MadisonInsiderSell910$7.67$6,979.70View SEC Filing  
4/28/2017Scott A. HolmesCFOSell1,219$5.89$7,179.91View SEC Filing  
4/24/2017John F. NeylanInsiderSell1,209$5.73$6,927.57View SEC Filing  
4/17/2017Brian AdamsGeneral CounselSell1,090$5.75$6,267.50View SEC Filing  
4/5/2017Brian AdamsGeneral CounselSell642$5.80$3,723.60View SEC Filing  
4/5/2017Greg MadisonInsiderSell911$5.80$5,283.80View SEC Filing  
1/30/2017Brian AdamsGeneral CounselSell6,984$4.65$32,475.60View SEC Filing  
1/30/2017Greg MadisonInsiderSell18,248$4.65$84,853.20View SEC Filing  
1/30/2017Scott A. HolmesCFOSell8,447$4.65$39,278.55View SEC Filing  
1/23/2017John F. NeylanInsiderSell1,428$5.39$7,696.92View SEC Filing  
1/17/2017Brian AdamsVPSell1,265$6.24$7,893.60View SEC Filing  
1/5/2017Brian AdamsVPSell759$6.16$4,675.44View SEC Filing  
1/5/2017Greg MadisonInsiderSell1,077$6.16$6,634.32View SEC Filing  
10/28/2016Scott A. HolmesCFOSell1,237$4.44$5,492.28View SEC Filing  
10/24/2016John F. NeylanInsiderSell1,211$4.72$5,715.92View SEC Filing  
10/17/2016Brian AdamsVPSell1,106$4.86$5,375.16View SEC Filing  
10/5/2016Brian AdamsVPSell647$5.38$3,480.86View SEC Filing  
10/5/2016Greg MadisonInsiderSell917$5.38$4,933.46View SEC Filing  
8/9/2016Greg MadisonInsiderSell1,622$4.22$6,844.84View SEC Filing  
7/29/2016Scott A. HolmesCFOSell4,935$7.36$36,321.60View SEC Filing  
7/25/2016John F. NeylanInsiderSell1,217$7.43$9,042.31View SEC Filing  
7/15/2016Brian AdamsVPSell1,083$7.01$7,591.83View SEC Filing  
7/5/2016Brian AdamsVPSell660$6.66$4,395.60View SEC Filing  
7/5/2016Greg MadisonCEOSell936$6.66$6,233.76View SEC Filing  
5/9/2016Greg MadisonCEOSell1,873$5.42$10,151.66View SEC Filing  
4/25/2016John F NeylanInsiderSell4,766$5.21$24,830.86View SEC Filing  
4/15/2016Brian AdamsVPSell1,060$5.05$5,353.00View SEC Filing  
4/5/2016Brian AdamsVPSell759$4.50$3,415.50View SEC Filing  
4/5/2016Greg MadisonCEOSell1,078$4.50$4,851.00View SEC Filing  
2/9/2016Greg MadisonCEOSell1,938$3.23$6,259.74View SEC Filing  
1/15/2016Brian AdamsVPSell1,322$3.30$4,362.60View SEC Filing  
1/6/2016Brian AdamsVPSell3,004$5.16$15,500.64View SEC Filing  
1/6/2016Greg MadisonCEOSell4,261$4.83$20,580.63View SEC Filing  
11/4/2015Scott A. HolmesCFOBuy5,000$5.33$26,650.00View SEC Filing  
10/15/2015Brian AdamsVPSell1,011$4.01$4,054.11View SEC Filing  
8/21/2015Scott A HolmesCFOBuy5,000$5.72$28,600.00View SEC Filing  
7/15/2015Brian AdamsVPSell1,086$9.99$10,849.14View SEC Filing  
7/6/2015James F Oliviero IIICFOSell1,943$9.61$18,672.23View SEC Filing  
5/6/2015Michael P TarnokDirectorBuy10,000$9.73$97,300.00View SEC Filing  
4/15/2015Brian AdamsVPSell4,320$12.40$53,568.00View SEC Filing  
4/6/2015James F Oliviero IIICFOSell1,878$11.68$21,935.04View SEC Filing  
4/6/2015Ron BentsurCEOSell1,592$11.68$18,594.56View SEC Filing  
3/6/2015Greg MadisonCOOBuy6,380$12.53$79,941.40View SEC Filing  
2/9/2015Greg MadisonCOOSell6,759$10.95$74,011.05View SEC Filing  
1/5/2015James F Oliviero IIICFOSell5,604$13.79$77,279.16View SEC Filing  
1/5/2015Ron BentsurCEOSell5,574$13.79$76,865.46View SEC Filing  
12/30/2014Ron BentsurCEOSell200,000$14.11$2,822,000.00View SEC Filing  
12/29/2014Ron BentsurCEOSell338,977$13.98$4,738,898.46View SEC Filing  
10/6/2014Ron BentsurCEOSell70,838$15.88$1,124,907.44View SEC Filing  
10/3/2014James F Oliviero IIICFOSell2,694$16.14$43,481.16View SEC Filing  
9/12/2014Ron BentsurCEOSell50,000$14.24$712,000.00View SEC Filing  
9/8/2014James F Oliviero IIICFOSell144,237$15.88$2,290,483.56View SEC Filing  
7/7/2014James F Oliviero IIICFOSell2,054$15.75$32,350.50View SEC Filing  
7/7/2014Ron BentsurCEOSell1,788$15.75$28,161.00View SEC Filing  
4/3/2014James Oliviero IIICFOSell2,087$16.46$34,352.02View SEC Filing  
4/3/2014Ron BentsurCEOSell1,816$16.46$29,891.36View SEC Filing  
3/21/2014James Oliviero IIICFOSell292,483$15.14$4,428,192.62View SEC Filing  
1/3/2014James Oliviero IIICFOSell6,309$12.57$79,304.13View SEC Filing  
1/3/2014Ron BentsurCEOSell5,257$12.57$66,080.49View SEC Filing  
12/30/2013James Oliviero IIICFOSell109,500$12.64$1,384,080.00View SEC Filing  
10/3/2013James Oliviero IIICFOSell1,475$10.25$15,118.75View SEC Filing  
10/3/2013Ron BentsurCEOSell2,505$10.25$25,676.25View SEC Filing  
7/5/2013James F Oliviero IIICFOSell1,438$7.95$11,432.10View SEC Filing  
7/5/2013Ron BentsurCEOSell2,440$7.95$19,398.00View SEC Filing  
5/13/2013James F Oliviero IIICFOSell29,363$8.34$244,887.42View SEC Filing  
10/3/2012James F Oliviero IIICFOSell4,973$2.72$13,526.56View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Keryx Biopharmaceuticals (NASDAQ:KERX)
Latest Headlines for Keryx Biopharmaceuticals (NASDAQ:KERX)
DateHeadline logoKeryx Biopharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : KERX-US : October 16, 2017 - October 16 at 7:43 PM logoKeryx Biopharmaceuticals Announces Presentations of New Data at the American Society of Nephrology Kidney Week ... - GlobeNewswire (press release) - October 13 at 8:12 PM logoKeryx Biopharmaceuticals Announces Presentations of New Data at the American Society of Nephrology Kidney Week 2017 Annual Meeting - October 13 at 11:25 AM logoKERX Crosses Above Average Analyst Target - October 10 at 7:40 PM logoBefore You Buy Keryx Biopharmaceuticals Inc’s (KERX), You Should Consider This - October 10 at 7:40 PM logo$18.80 Million in Sales Expected for Keryx Biopharmaceuticals, Inc. (KERX) This Quarter - October 10 at 8:48 AM logoWhy the Bears Are Wrong About Keryx Biopharmaceuticals Stock - October 10 at 8:00 AM logoZacks: Analysts Expect Keryx Biopharmaceuticals, Inc. (KERX) Will Announce Earnings of -$0.17 Per Share - October 8 at 2:24 PM logoKeryx, Upcoming PDUFA Action on Label Expansion for Auryxia - October 6 at 2:22 AM logoKeryx Focuses on Kidney Drug Auryxia Despite Generic Threat - September 29 at 9:39 AM logoKeryx Biopharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : KERX-US : September 26, 2017 - September 26 at 10:04 AM logoHere's Why These 3 Biotech Stocks Might Stop Rallying (Revised) - Nasdaq - September 25 at 6:48 PM logoKeryx Biopharmaceuticals, Inc. (KERX) Receives Consensus Rating of "Hold" from Analysts - September 24 at 8:34 PM logoAnalyzing Keryx Biopharmaceuticals (KERX) & Its Rivals - September 24 at 10:20 AM logoHere's Why These 3 Biotech Stocks Might Stop Rallying - Nasdaq - September 21 at 8:37 AM logoHere's Why These 3 Biotech Stocks Might Stop Rallying - September 21 at 8:37 AM logoCritical Analysis: Keryx Biopharmaceuticals (KERX) vs. Its Peers - September 20 at 4:28 AM logoKeryx Biopharmaceuticals, Inc. (KERX) Expected to Post Earnings of -$0.17 Per Share - September 19 at 8:10 PM logoKeryx Biopharmaceuticals, Inc. (KERX) Catches Eye: Stock Jumps 5.9% - September 18 at 7:44 PM logoKeryx Biopharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : KERX-US : September 15, 2017 - September 16 at 3:44 AM logoKeryx Biopharmaceuticals Announces Changes to its Board of Directors - September 13 at 4:44 PM logoKeryx Biopharmaceuticals to Webcast its Presentations at Investor Healthcare Conferences in September 2017 - GlobeNewswire (press release) - September 5 at 10:03 PM logoKeryx Biopharmaceuticals to Webcast its Presentations at Investor Healthcare Conferences in September 2017 - September 5 at 5:01 PM logo Brokerages Anticipate Keryx Biopharmaceuticals, Inc. (KERX) Will Announce Quarterly Sales of $18.80 Million - September 3 at 8:48 AM logoKeryx Biopharmaceuticals, Inc. – Value Analysis (NASDAQ:KERX) : September 2, 2017 - September 2 at 2:38 AM logoKeryx Biopharmaceuticals, Inc. (KERX) Given Consensus Rating of "Hold" by Brokerages - August 30 at 8:36 PM logoKeryx Biopharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : KERX-US : August 29, 2017 - August 29 at 3:22 PM logoShort Interest in Keryx Biopharmaceuticals, Inc. (KERX) Drops By 8.1% - August 27 at 4:04 AM logoETFs with exposure to Keryx Biopharmaceuticals, Inc. : August 11, 2017 - August 12 at 1:31 AM logoKeryx Biopharmaceuticals: Catalyst In Upcoming FDA Decision - Seeking Alpha - August 10 at 5:00 AM logoCaptain Keryx Beams Up Sales - August 8 at 12:37 AM logoKeryx Biopharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : KERX-US : August 7, 2017 - August 7 at 7:36 PM logoKeryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Given Consensus Recommendation of "Hold" by Brokerages - August 5 at 8:56 PM logoKeryx Biopharmaceuticals to Webcast its Presentation at Canaccord Genuity’s 37th Annual Growth Conference on August 9, 2017 - August 4 at 11:47 PM logoJohn F. Neylan Sells 1,445 Shares of Keryx Biopharmaceuticals, Inc. (KERX) Stock - August 1 at 8:22 PM logoCommit To Purchase Keryx Biopharmaceuticals At $4, Earn 13.8% Using Options - August 1 at 12:39 AM logoKeryx Biopharmaceuticals' (KERX) CEO Greg Madison on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha - July 29 at 12:58 AM logoKeryx (KERX) Posts Wider than Expected Loss in Q2, Sales Beat - July 29 at 12:58 AM logoKeryx Biopharmaceuticals, Inc. :KERX-US: Earnings Analysis: Q2, 2017 By the Numbers : July 28, 2017 - July 29 at 12:58 AM logo$17.58 Million in Sales Expected for Keryx Biopharmaceuticals, Inc. (KERX) This Quarter - July 28 at 1:59 PM logoKeryx (KERX) Posts Wider-than-Expected Q2 Loss, Sales Beat - Nasdaq - July 28 at 1:13 AM logoKeryx Biopharmaceuticals Announces Second Quarter 2017 Financial Results and Increased 2017 U.S. Product Sales Guidance - July 28 at 1:13 AM logoKeryx (KERX) Posts Wider-than-Expected Q2 Loss, Sales Beat - July 28 at 1:13 AM logoEdited Transcript of KERX earnings conference call or presentation 27-Jul-17 12:00pm GMT - July 28 at 1:13 AM logoETFs with exposure to Keryx Biopharmaceuticals, Inc. : July 27, 2017 - July 28 at 1:13 AM logoKeryx Biopharma reports 2Q loss - July 28 at 1:13 AM logoKeryx Biopharmaceuticals, Inc. (KERX) Releases Quarterly Earnings Results, Misses Estimates By $0.60 EPS - July 28 at 12:21 AM logoKeryx Biopharmaceuticals, Inc. (KERX) Earns "Equal Weight" Rating from Morgan Stanley - July 25 at 8:17 PM logoKeryx Biopharmaceuticals, Inc. (KERX) Rating Reiterated by Cowen and Company - July 25 at 12:12 PM logoWhat to Expect from Keryx (KERX) this Earnings Season? - July 22 at 5:15 AM



Keryx Biopharmaceuticals (KERX) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.